Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors

Stem Cells

Volumn 24, Issue 7, 2006, Pages 1789-1797

  Shaughnessy, Paul J ^a,c   Bachier, Carlos ^a   LeMaistre, Charles F ^a   Akay, Cagla ^b   Pollock, Brad H ^b   Gazitt, Yair ^b  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c 8201 Ewing Halsell ^*  (United States)

Author keywords

Dentritic cells; Graft versus host disease; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Mobilization

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CD34 SELECTION; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DONOR; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; NORMAL HUMAN; POLARIZATION; STEM CELL; ALLOTRANSPLANTATION; BLOOD; BLOOD DONOR; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CELL POLARITY; CLINICAL TRIAL; COMPARATIVE STUDY; GRAFT VERSUS LEUKEMIA EFFECT; LYMPHOCYTE TRANSFUSION; METABOLISM; MIDDLE AGED; PILOT STUDY; TH1 CELL;

ADULT; BLOOD DONORS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CELL POLARITY; DENDRITIC CELLS; FEMALE; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; PILOT PROJECTS; TH1 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33749042843     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2005-0492     Document Type: Article

References (47)

1. Kolb, HJ. Management of relapse after hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science, Inc., 1999;929-936.
2. Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
3. Giralt SA, Kolb HJ. Donor lymphocyte infusions. Curr Opin Oncol 1996;8:96-102.
4. Kolb HJ, Schattenberg A, Goldman JM et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
5. Slavin S, Naparstek E, Nagler A et al. Allogenic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.
6. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem cell transplantation: Predictive factors for response and long term outcome. J Clin Oncol 2000;18:3031-3037.
7. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179-1184.
8. Bierman PJ. Allogeneic bone marrow transplantation for lymphoma. Blood Rev 2000;14:1-13.
9. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. N Engl J Med 2000;343:750-758.
10. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablatives stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756.
11. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft versus leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
12. Khouri I, Keating M, Korbling M et al. Transplant-lite: Induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
13. Childs R, Epperson D, Bahceci E et al. Molecular remission of chronic myeloid leukaemia following a non myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft versus leukaemia effect. Br J Haematol 1999;107:396-400.
14. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
15. + cells mobilized with different growth factors. STEM CELLS 2001;18:390-398.
16. Gazitt Y. Recent developments in the regulation of peripheral blood stem cell mobilization. J Hematother Stem Cell Res 2001;10:229-236.
17. Gazitt Y. Comparison between G-CSF and GM-CSF in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002;9:190-198.
18. Gazitt Y, Shaughnessy P, Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J. Hematother Stem Cell Res 2001;10:177-186.
19. Peters WP, Rosner G, Ross M et al. Comparative effect of GM-CSF and G-CSF on priming of peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy. Blood 1993;81:1709-1719.
20. Kiertscher SM, Roth, MD. Human CD14 leukocytes acquire the phenotype and function of antigen presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukocyte Biol 1996;59:208-218.
21. + cells in cancer patients. Cancer Res 2000;60:1934-1941.
22. Caux C, Dezutter Dambuyant C, Schmitt D et al. GM-CSF and TNF-alpha co-operate in the generation of dendritic Langerhans cells. Nature 1992;360:258-261.
23. + cells identifies immunocompetent committed precursors of macrophages and dendritic cells. Blood 1998;91:3892-3900.
24. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Blood 1995;87:1292-1302.
25. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: Lineages, plasticity and kinetics. Curr Opin Immunol 2001;2:725-731.
26. Shortman K, Liu Y-J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-161.
27. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9.
28. Agrawal S, Agrawal A, Doughty B et al. Cutting edge: Different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol 2003;171:4984-4989.
29. Avigan D, Wu Z, Gong J et al. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res 1999;5:2735-2741.
30. Morse MA, Vredenburgh JJ, Lyerly HK et al. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. J Hematother Stem Cell Res 1999;8:577-584.
31. Arpinati M, Green CL, Heimfeld S et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000;95:2484-2490.
32. Hock BD, Haring LF, Ebbett AM et al. Differential effects of G-CSF mobilisation on dendritic cell subsets in normal allogeneic donors and patients undergoing autologous transplantation. Bone Marrow Transplant 2002;30:733-740.
33. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002;30:495-501.
34. Ferrari S, Rovati B, Porta C et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunol Immunother 2003;52:359-366.
35. Lonial S, Hicks M, Rosenthal H et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004;10:848-857.
36. Gazitt Y, Akay C, Thomas C. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-Hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev 2006;15:269-277.
37. Waller E, Rosenthal H, Jones T et al. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001;97:2948-2956.
38. + cells in normal donors. Blood 2004;11:2870.
39. Common Terminology Criteria for Adverse Events. Version 3.0 December 12, 2003. Available at http://ctep.cancer.gov/reporting/CTC-3.html. Accessed July 4, 2004.
40. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974;18:295-304.
41. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high dose chemotherapy. Blood 1993;86:180-182.
42. Sanchez J, Herrera C, Torres A et al. Chemotherapy plus G-CSF mobilized peripheral blood stem cell harvests from acute myeloid leukaemia patients contain large amounts of polyclonal myeloid linnegCD11cpos dendritic precursor cells. Br J Haematol 2004;124:636-644.
43. + lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors. Stem Cells Dev 2005;14:310-316.
44. Tayebi H, Kuttler F, Saas P et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001;29:458-470.
45. Shier LR, Schultz KR, Imren S et al. Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. Biol Blood Marrow Transplant 2004;10:624-634.
46. Gazitt Y, Callander N, Freytes CO et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF followed by G-CSF in non Hodgkin's lymphoma patients: A randomized prospective study. J Hematother Stem Cell Res 2000;9:737-748.
47. Arat M, Arslan O, Gurman G et al. The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy. Transfus Apher Sci 2004;30:9-15.